(Q36577174)

15 August 2017

title

Reappraisal of 2003 NKF-K/DOQI guidelines for management of hyperparathyroidism in chronic kidney disease patients (English)

1 reference

chronic renal insufficiency

15 August 2017

1 reference

1 reference

Matthieu Monge

1

1 reference

15 August 2017

Irina Shahapuni

2

1 reference

15 August 2017

Roxana Oprisiu

3

1 reference

15 August 2017

Najeh El Esper

4

1 reference

15 August 2017

Philippe Morinière

5

1 reference

15 August 2017

Ziad Massy

6

1 reference

15 August 2017

Gabriel Choukroun

7

1 reference

15 August 2017

Albert Fournier

8

1 reference

15 August 2017

publication date

1 June 2006

1 reference

Nature Clinical Practice Nephrology

15 August 2017

published in

1 reference

15 August 2017

volume

2

1 reference

15 August 2017

issue

6

1 reference

15 August 2017

page(s)

326-336

1 reference

Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

STUDIES OF CALCIUM AND PHOSPHORUS METABOLISM WITH SPECIAL REFERENCE TO PATHOGENESIS AND EFFECTS OF DIHYDROTACHYSTEROL (A.T.10) AND IRON

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

Etiology of hyperparathyroidism and bone disease during chronic hemodialysis. I. Association of bone disease with potentially etiologic factors

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

Etiology of hyperparathyroidism and bone disease during chronic hemodialysis. II. Factors affecting serum immunoreactive parathyroid hormone

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

High dialysate calcium may improve the efficacy of calcimimetic treatment in hemodialysis patients with severe secondary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser's zones independent of calcitriol?

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

Serum 25(OH)-vitamin D levels and bone metabolism in patients on maintenance hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

Unique Biosynthesis by Kidney of a Biologically Active Vitamin D Metabolite

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

Vitamin D receptor: mechanisms for vitamin D resistance in renal failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

Dietary calcium and phosphorus ratio regulates bone mineralization and turnover in vitamin D receptor knockout mice by affecting intestinal calcium and phosphorus absorption

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

Targeted ablation of the 25-hydroxyvitamin D 1alpha -hydroxylase enzyme: evidence for skeletal, reproductive, and immune dysfunction

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

p21WAF1 and TGF-alpha mediate parathyroid growth arrest by vitamin D and high calcium

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

Reversal of secondary hyperparathyroidism by phosphate restriction restores parathyroid calcium-sensing receptor expression and function.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

The phosphatonin pathway: new insights in phosphate homeostasis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

Treatment of secondary hyperparathyroidism by high calcium diet is associated with enhanced resistance artery relaxation in experimental renal failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

High calcium diet down-regulates kidney angiotensin-converting enzyme in experimental renal failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

The calcium-sensing receptor is required for normal calcium homeostasis independent of parathyroid hormone

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

Rescue of the skeletal phenotype in CasR-deficient mice by transfer onto the Gcm2 null background

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

On the mechanism of secondary hyperparathyroidism in moderate renal insufficiency

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

Dietary intake of phosphorus modulates the circadian rhythm in serum concentration of phosphorus. Implications for the renal production of 1,25-dihydroxyvitamin D

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

Ketodiet, physiological calcium intake and native vitamin D improve renal osteodystrophy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

Low-dose calcitriol prevents the rise in 1,84-iPTH without affecting serum calcium and phosphate in patients with moderate renal failure (prospective placebo-controlled multicentre trial)

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

Comparison of 1 alpha-OH-vitamin D3 and high doses of calcium carbonate for the control of hyperparathyroidism and hyperaluminemia in patients on maintenance dialysis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Durham Renal Osteodystrophy Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

Premature aging-like phenotype in fibroblast growth factor 23 null mice is a vitamin D-mediated process

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

Systemic cardiovascular disease in uremic rats induced by 1,25(OH)2D3.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

Controlled trial of 1apha-hydroxycholecalciferol in chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

Deterioration of renal function during treatment of chronic renal failure with 1,25-dihydroxycholecalciferol

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

Vascular calcification in long-term haemodialysis patients in a single unit: a retrospective analysis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

Effects of oral and intravenous calcitriol on serum calcium oxalate saturation in dialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

Dyslipidemia and progression of cardiovascular calcification (CVC) in patients with end-stage renal disease (ESRD).

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

Arterial calcifications and bone histomorphometry in end-stage renal disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

Evaluation of vascular calcinosis risk factors in patients on chronic hemodialysis: lack of influence of calcium carbonate

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

Activated injectable vitamin D and hemodialysis survival: a historical cohort study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

25-hydroxyvitamin D3-1alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

Antiproteinuric effect of oral paricalcitol in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

Vitamin D deficiency: a neglected aspect of disturbed calcium metabolism in renal failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

Long-term (6 months) cross-over comparison of calcium acetate with calcium carbonate as phosphate binder

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

Nicotinamide suppresses hyperphosphatemia in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

Efficacy and safety of an extended-release niacin (Niaspan): a long-term study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

Thrombocytopenia induced by nicotinamide in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

N-methyl-2-pyridone-5-carboxamide: a novel uremic toxin?

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0189

7 January 2021

Identifiers

DOI

10.1038/NCPNEPH0189

1 reference

15 August 2017

1 reference